Inotuzumab Ozogamicin bulk supplier for pharma manufacturers

Inotuzumab Ozogamicin 1 mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 1 mg

Reference Brands: Besponsa (USA/LATAM)

Inotuzumab Ozogamicin is a Oncology Cancer Care product available as Injection in strengths 1 mg. It corresponds to the reference brand Besponsa (USA/LATAM). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Inotuzumab ozogamicin is a targeted anticancer therapy classified as a monoclonal antibody–drug conjugate (ADC) used primarily for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The medicine combines a humanized monoclonal antibody that specifically targets the CD22 antigen found on malignant B cells with a potent cytotoxic agent called calicheamicin. Once the drug binds to CD22-positive leukemia cells, it is internalized into the cell, where the cytotoxic component is released to damage DNA and trigger cell death. This targeted approach helps deliver the chemotherapy directly to cancer cells while limiting exposure to normal tissues.

Inotuzumab ozogamicin has shown significant effectiveness in patients who have not responded well to previous treatments or whose disease has returned after therapy. It can help achieve remission and may serve as a bridge to stem cell transplantation in eligible patients. However, treatment requires careful monitoring because the drug can cause side effects, including low blood cell counts, infections, and liver-related complications. One of the most important risks associated with this therapy is sinusoidal obstruction syndrome, a serious liver condition that can occur during or after treatment. Due to these potential risks, therapy is typically managed by oncology specialists with regular clinical and laboratory monitoring to ensure patient safety and treatment effectiveness.

Inotuzumab Ozogamicin — third party manufacturing & bulk supply

Inotuzumab Ozogamicin 1 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Inotuzumab Ozogamicin is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Inotuzumab Ozogamicin listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Inotuzumab Ozogamicin →

Back to Listing

Frequently Asked Questions

Inotuzumab ozogamicin is used for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults. It is prescribed when the disease has returned after previous treatment or has not responded to other therapies.

Inotuzumab ozogamicin is an antibody–drug conjugate composed of a monoclonal antibody that targets the CD22 protein on B cells, linked to a cytotoxic agent that helps destroy leukemia cells after the drug binds to them.

The primary trade name of Inotuzumab ozogamicin is Besponsa.

Inotuzumab ozogamicin (Besponsa) is developed and marketed by Pfizer.

The generic name is Inotuzumab ozogamicin.

The main brand name is Besponsa.

Inotuzumab ozogamicin is manufactured in GMP-certified biologics production facilities approved by regulatory authorities such as the US FDA, EMA, and other international agencies depending on the region of supply.